Biodesix BDSX 深 滬
等待開盤 09-23 09:30:00 美东时间
28.15
-0.280
-0.98%
華盛通- 最 高29.065
- 今 開28.37
- 成交量 5.70万股
- 最 低 27.75
- 昨 收 28.43
- 總市值 2.97亿
- 52周最高 31.31
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 5.26
- 委 比 78.57%
- 總股本 1055.11万
- 歷史最高 639.80
- 量 比 0.63
- 振 幅 4.63%
- 歷史最低 3.436
- 每 手 1
- 風險率 6.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Analysts’ Top Healthcare Picks: Abivax SA Sponsored ADR (ABVX), Biodesix (BDSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-22 21:50
Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Biodesix's Vice President of Quality and Regulatory Affairs, Brianna Phillips, will present at the RAPS and SOCRA Annual Meetings, showcasing the company's QA/RA excellence. Under her leadership, Biodesix has achieved significant certifications and successful audits, enhancing its diagnostic blood tests for lung nodule patients. Phillips also contributes to industry education and leadership, aiming to advance patient care and outcomes.
09-14 20:01
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. announced that its leadership team will participate in three upcoming investor conferences in New York: the 10th Annual BIG10 Conference on September 10, the 28th Annual H.C. Wainwright Global Investment Conference on September 15, and the 5th Annual Roth Healthcare Opportunities Conference on September 29, featuring a panel discussion on MRD monitoring in solid tumors led by Gary Pestano, Ph.D.
09-03 10:00
Biodesix Earnings Call Highlights Rapid Growth Path
Biodesix, Inc. (($BDSX)) has held its Q2 earnings call. Read on for the main hi...
08-17 08:23
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
08-07 02:34
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
Biodesix, Inc. announced that its leadership team will participate in a fireside chat and host investor meetings at Canaccord Genuity’s 46th Annual Growth Conference on August 11-12, 2026. The fireside chat will take place on August 12 at 3:30 PM ET in Boston, MA. Biodesix, a leading diagnostic solutions company, offers tests like Nodify Lung® and IQLung® to improve outcomes for lung disease patients. The presentation will be available via webcas...
08-04 10:00
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
Biodesix, Inc. (Nasdaq: BDSX) announced it will release its second-quarter 2026 financial results after market close on August 5, 2026. Management will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update. Registration links for the webcast and Q&A session are available. Biodesix is a leading diagnostic solutions company focused on improving clinical care and patient outcomes thro...
07-22 10:00
